The patient continued treatment with the same dose of crizotinib for 20 weeks and showed evidence of progressive disease PD with bone metastasis at 63 weeks. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. Support Center Support Center. Currently, strategies aiming to maximize treatment benefit for NSCLC are centered on individualized treatments based on the molecular profile of the disease. However, information concerning clinical experience and management of severe neutropenia is currently limited. It is possible that the efficacy of pemetrexed in the present case was associated with ALK positivity. Subgroup analysis by type of chemotherapy showed that median PFS was significantly higher with crizotinib than with either pemetrexed HR:
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Open in a separate window. C Chest CT at the start of pemetrexed treatment revealed pulmonary tumors in the left upper lobe with enlargement of the hilar lymph nodes. A year-old woman was admitted to our hospital with a left pleural effusion. Written informed consent was obtained from the patient for publication of this case report. Median PFS was significantly higher in the crizotinib group 7.
Limited clinical experience and information concerning the management of AEs associated with both crizotinib and alectinib treatment is currently available. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. Furthermore, in the present case, the FFPE tissue specimen used for determining ALK-positivity was obtained from a metastatic tumor of the cass. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
View large Download slide. Therefore, this disease may be diagnosed using previously obtained samples.
It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Disclosure Statement All studu have no potential conflicts of interest. Thus, we conclude that the pathogenesis of neutropenia in the present case might be associated with the inhibitory action against the c-Met receptor rather than an immune-mediated reaction.
In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia.
XALKORI case study
As a result, there is an unmet clinical need in advanced NSCLC, with potential to improve outcomes by identifying distinct molecular subtypes of patients who may casse to specific targeted therapies. Patients receiving crizotinib also had a significantly longer time to worsening of lung cancer symptoms cough, dyspnoea or chest pain compared with chemotherapy HR: Receive exclusive offers and updates from Oxford Academic.
B Pelvic CT at diagnosis revealed a multilocular tumor in the acse ovary. Oxford University Press is a department of the University of Oxford.
Bone health in childhood cancer: Close mobile search navigation Article navigation. Several ALK inhibitors have been introduced in clinical trials or are currently under preclinical development.
Thus, all medicines, including crizotinib, were discontinued at that time. Crizotinib, Anaplastic lymphoma kinase gene rearrangement, Neutropenia, Alectinib, Non-small cell lung cancer.
studt A notable difference in the myelotoxicity between crizotinib and alectinib treatment was observed in the present patient. Gastrointestinal endoscopy is usually required for the diagnosis of esophagitis, which supports the hypothesis that more cases of undocumented esophagitis may have occurred in patients undergoing crizotinib treatment compared with what was actually reported.
These patients were enrolled into an expanded cohort of an ongoing phase I study PROFILE and received crizotinib mg twice daily in day cycles, a dose which was established casw the dose-escalation phase of the study. Abstract Non-small-cell lung cancer NSCLC is the most commonly diagnosed type of cancer and is a leading cause of cancer-related mortality worldwide.
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Before beginning crizotinib, patients should be warned that visual disturbances may occur and that they might affect activities such as driving in the dark [ 34 ].
XALKORI case study | TIGCRU Insight
Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Written informed consent was obtained from the patient for publication of this case report.
Although grade 1 AEs including visual disturbance and nausea were noted 3 days after administration of crizotinib, a partial response was achieved at 4 weeks. Eight days later the patient developed severe nausea and vomiting and esophagitis was diagnosed by gastrointestinal endoscopic examination. The ITT population in PROFILE comprised patients randomised to crizotinib and to chemotherapy who at the time of the primary analysis had been followed up for a median of National Center for Biotechnology InformationU.
In this case report, the details of the clinical course of a patient with severe neutropenia induced by crizotinib are described. The CNS is one of the principal sites of disease progression for patients receiving crizotinib therapy [ 31 ].
Abstract Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase ALK gene rearrangement, is generally well tolerated.